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The rat I~-tropomyosin (13-TM) gene encodes both skeletal muscle 13-TM and fibroblast TM-1 by an alternative 
RNA-splicing mechanism. This gene contains 11 exons. Exons 1-5, 8, and 9 are common to all mRNAs 
expressed from the gene. Exons 6 and 11 are used in fibroblasts as well as smooth muscle cells, whereas exons 
7 and 10 are used in skeletal muscle cells. In this study we have carried out an extensive mutational analysis 
to identify c/s-acting elements that block the use of the skeletal muscle-specific exon 7 in nonmuscle cells. 
These studies localize the critical elements for regulated alternative splicing to sequences within exon 7 and 
the adjacent upstream intron. In addition, mutations that inactivate the 5'- or 3'-splice sites of exon 6 do not 
result in the use of the skeletal muscle-specific exon 7 in nonmuscle cells, suggesting that splice-site selection 
in vivo is not regulated by a simple c/s-acting competition mechanism but, rather, by a mechanism that 
inhibits the use of exon 7 in certain cellular environments. In support of this hypothesis we have identified 
sequence-specific RNA-binding proteins in HeLa cell nuclear extracts using native gel electrophoresis and 
binding competition assays. Mutations in the pre-mRNA that result in the use of the skeletal muscle exon in 
vivo also disrupt he binding of these proteins to the RNA in vitro. We propose that the binding of these 
proteins to the pre-mRNA is involved in regulated alternative splicing and that this interaction is required for 
blocking the use of the skeletal muscle exon in nonmuscle cells. 
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Alternative RNA splicing is a fundamental process in 
eukaryotes that contributes to tissue-specific and devel- 
opmentally regulated patterns of gene expression (Smith 
et al. 1989; McKeown 1990). At present, relatively little 
is known about he cellular factors and mechanisms that 
are responsible for the selection of alternative splice sites 
in complex transcription units and how the splicing sig- 
nals in alternatively spliced exons differ from those in 
constitutively spliced exons (for review, see Smith et al. 
1989; McKeown 1990; Maniatis 1991). Significant prog- 
ress has been made in Drosophila systems uch as in the 
genes of the sex-determination pathway, suppressor f
white apricot and Drosophila P-transposase. In these 
systems alternative splicing is subject to regulation by 
factors that either inhibit or activate the use of alterna- 
tive 5'- or 3'-splice sites (McKeown 1990; Hedley and 
Maniatis 1991; Maniatis 1991 ). In contrast, in vertebrate 
systems, much less is known about the mechanisms and 
4Corresponding author. 
cellular factors involved in regulated alternative splic- 
ing, but a number of features in the pre-mRNA have 
been implicated in alternative splice-site selection. 
These include the relative strengths of 5'- and 3'- splice 
sites (Zhuang et al. 1987; Kuo et al. 1991; Mullen et al. 
1991), intron size (Fu and Manley 1987), the pyrimidine 
content of a 3'-splice site (Fu et al. 1988; Mullen et al. 
1991), the location of branchpoints (Gattoni et al. 1988; 
Helfman and Ricci 1989; Smith and Nadal-Ginard 1989; 
Goux-Pelletan et al. 1990; Helfman et al. 1990), multiple 
alternative branchpoints (Noble et al. 1987, 1988; Gat- 
toni et al. 1988; Helfman and Ricci 1989), branchpoint 
sequences (Reed and Maniatis 1988; Zhuang et al. 1989; 
Mullen et al. 1991 ), intron sequences between a3'-splice 
site and upstream branchpoint (Goux-Pelletan et al. 
1990; Helfman et al. 1990; Libri et al. 1990), and exon 
sequences (Reed and Maniatis 1986; Mardon et al. 1987; 
Somaseker and Mertz 1985; Helfman et al. 1988; Cooper 
and Ordahl 1989; Hampson et al. 1989; Streuli and Saito 
1989; Black 1991; Libri et al. 1990, 1991). 
In addition to cis-acting elements in the pre-mRNA, at 
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least one cellular factor isolated from mammalian cells, 
termed ASF (alternative splicing factor) or SF2, has been 
found to affect the choice of alternative 5'-splice sites 
(Ge and Manley 1990; Krainer et al. 1990a). In vitro splic- 
ing studies with the early region of simian virus (SV40) 
involving the large T- and small t-splice choices, and 
model pre-mRNA substrates derived from the human 
f~-globin gene demonstrated that igh concentrations of 
ASF/SF2 promote the use of proximal 5'-splice sites, 
whereas low concentrations favor the use of distal 5' 
splice sites (Ge and Manley 1990; Krainer et al. 1990a). 
Although this factor is also required for general splicing 
(Krainer et al. 1990b), differences in the relative concen- 
trations or activities of this factor in different cell types 
could, in principle, play a role in regulated alternative 
splicing. 
The tropomyosin genes represent an excellent system 
to study the molecular basis for tissue-specific RNA 
splicing. Tropomyosins are a diverse group of actin-bind- 
ing proteins found in all eukaryotic ells, with distinct 
isoforms found in muscle (skeletal, cardiac, and smooth), 
brain, and various nonmuscle cells. In many animals, 
such as nematodes, flies, frogs, birds, and mammals, this 
isoform diversity is generated by a combination of mul- 
tiple genes, most of which exhibit alternative splicing of 
primary RNA transcripts (forreview, see Lees-Miller and 
Helfman 1991). We have been using the rat ~-tropomy- 
osin (~-TM) gene as a model system to investigate the 
mechanisms responsible for developmental nd tissue- 
specific alternative RNA splicing (Helfman et al. 1986, 
1988, 1990; Helfman and Ricci 1989). This gene spans 10 
kb of DNA with 11 exons and encodes two distinct iso- 
forms, namely skeletal muscle f~-TM and fibroblast 
tropomyosin-1 (TM-1). Exons 1-5, 8, and 9 are common 
to all mRNAs expressed from this gene. Exons 6 and 11 
are used in fibroblasts, as well as in smooth muscle, 
whereas exons 7 and 10 are used exclusively in skeletal 
muscle. Our previous tudies of tropomyosin pre-mRNA 
splicing with HeLa cell (nonmuscle) systems revealed an 
ordered pathway of splicing in which either of the inter- 
nal alternatively spliced exons (exon 6 or 7) must first be 
joined to the downstream common exon before they can 
be spliced to the upstream common exon (Helfman et al. 
1988). Unlike most branchpoints that have been 
mapped, in which a single adenosine residue located 18- 
40 nucleotides from a 3'-splice site is used during lariat 
formation {Green 1986), in vitro splicing of exon 5 to 
exon 7 (skeletal muscle-type splice) involved the use of 
multiple branchpoints hat are located an unusually long 
distance (144, 147, and 153 nucleotides) from the 3'- 
splice site of exon 7 {Helfman and Ricci 1989). Subse- 
quently, we investigated the functional role of the intron 
sequences between the distant branchpoints and the 3'- 
splice site of the skeletal muscle exon 7. Our results 
demonstrated that two distinct functional elements are 
present in this region (Helfman et al. 1990). The first 
element is comprised of a polypyrimidine tract located 
89-143 nucleotides upstream of the 3'-splice site, which 
specifies the location of the branchpoints used, 144-153 
nucleotides upstream of exon 7. The second element is 
comprised of intron sequences located between the poly- 
pyrimidine tract and the 3'-splice site of exon 7. This 
region contains an important determinant in alternative 
splice site selection because deletion of these sequences 
results in the use of the skeletal muscle-specific exon in 
nonmuscle cells (Helfman et al. 1990). 
To study further how these sequences prevent he use 
of exon 7 in nonmuscle cells, we carried out an extensive 
mutational analysis of the intron sequences upstream 
and downstream ofexon 7, as well within the exon itself. 
These studies how that the critical cis-acting elements 
for regulated alternative splicing are confined to se- 
quences within exon 7 and the adjacent upstream intron. 
We also demonstrate that these sequences function, in 
part, to regulate splice-site selection in vivo by interact- 
ing with cellular factors and thereby block the use of the 
skeletal muscle exon in nonmuscle cells. 
Resu l ts  
Nucleotide substitutions within intron 6 result 
in use of the skeletal muscle-specific exon 7 
in nonmuscle cells 
To localize further the cis-acting elements involved in 
splice site selection, we constructed a series of mini- 
genes containing clustered point mutations in intron 6 
(Fig. 1). These mutations do not alter the distance be- 
tween the 3'-splice site of exon 7 and the upstream 
branchpoints, and result in only 3-5 nucleotide substi- 
tutions. This approach was chosen to determine whether 
the deletion mutations, which resulted in the use of the 
skeletal muscle-type splice in nonmuscle cells, altered 
splice site selection by simply altering the distance be- 
tween the 3'-splice site and upstream branchpoints orby 
removing specific inhibitory sequences {Helfman et al. 
1990). The sequence of intron 6 and the positions of the 
substitutions in this intron are indicated in Figure 1. The 
mutations were introduced into plasmid pSV40-2 for in 
vivo analyses (Helfman et al. 1988, 1990). Plasmid 
pSV40-2 carries a minigene consisting of the SV40 early 
promoter and a functional poly(A) site flanking genomic 
tropomyosin sequences. We have demonstrated previ- 
ously that transient expression of wild-type plasmid 
pSV40-2 in HeLa cells resulted in spliced RNA that con- 
tains exons 5 + 6 + 8 + 9 and very little detectable v- 
els of spliced RNA containing the skeletal muscle-type 
splice products, that is, exons 5 + 7 + 8 + 9 (Helfman 
et al. 1988, 1990). HeLa cells were transfected with the 
wild-type and six clustered point mutation plasmids 
(int-1 through int-6), and 48 hr later the cytoplasmic 
RNA was isolated and analyzed by RNase protection. 
The RNase protection analyses of these RNAs and of 
RNA isolated from mock-infected cells were carried out 
with RNA probes derived from cDNA clones encoding 
rat fibroblast TM-1 and skeletal muscle ~-TM (Fig. 2A). 
Transient expression of the wild-type plasmid pSV40-2 
in HeLa cells resulted in spliced RNA that contains ex- 
ons 5 + 6 + 8 + 9. Only low levels of the skeletal mus- 
cle-type splice with the wild-type construct, that is, ex- 
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guaguagccucucuaggccuuucuaggcaauggcaccuuuucucacuuca -- 
cgucccuccccagcucagcaucucaggcuacugucucucuccugcgguag 
. , . 
gagggggcgggggcggagcuuccaaacagccugcugucacucucaucac__u 
uuqcucuucucuuuucuccuccuccccuccuccacuquqccaccccuccc 
int-I int-2 int-3 
ccuaaccccacccccucaccccgucgucgcgCcaccccacugucucaccu 
GGAUCC GGAUCC GGAUCC 
int-4 int-5 int-6 
ca cug~gccc ucacgcuccauccugcca cacgccccugc ag 
GGAUCC GGAUCC GGAUCC 
Intron 6 
Ex-I Ex-2 1 UAAAUGUGGGGACCUAGA~GCUGAAAAUUGUUACCAA 
GGAUCC GGAUCC 
Ex-3 Ex-4 Exon 7 
CAACLK/C4KAAUCUCUGGAAGCC~GGACAAG 
GGAUCC GGAUCC 
d6 d5 d4 d5 --] 
guauaggg~ggaggggdgcguguga~gaaggggcutgugccgagaggaggg 
I d2 dl gagggduuagguagggagggc~aggugcuuaaugaagaucaacccggagc 8su 56I Intron 7 ~ugagggguucagugucugcgaagguuucaggaucacugaagcgguucac ugacggcacguguuugucucuuaaag 
Figure 1. Nucleotide sequence of substitutions and mutations 
within the B-TM pre-mRNA. The nucleotide sequence of intron 
6, exon 7, and intron 7, respectively, are shown. The positions of 
the lariat branchpoints used in splicing exon 5 to exon 7, which 
are located 144, 147, and 153 nucleotides upstream of exon 7 are 
indicated (*). The 55-nucleotide-long polypyrimidine tract lo- 
cated 89-143 nucleotides upstream from the 3'-splice site of 
exon 7 is underlined. Nucleotide substitutions in intron 6 and 
exon 7, which introduced a BamHI site, are indicated int-1 
through int-6 for mutations in the 3' end of intron 6 and Ex-1 
through Ex-4 for mutations in exon 7. (dl--d6) Deletions in in- 
tron 7, beginning at a Bsu36I site located 75 bases upstream of 
exon 8, and going toward the 5' end of intron 7. 
ons 5 + 7 + 8 + 9, were detected (Fig. 2A, lane labeled 
W). In contrast, transient expression of the minigenes 
containing the mutations designated int-2 through int-5 
resulted in expression of two forms of spliced RNA: one 
containing exons 5 + 6 + 8 + 9, and the other contain- 
ing exons 5 + 7 + 8 + 9 (skeletal muscle-type splice) 
(Fig. 2A). On the other hand, transient expression of mu- 
tants int-1 and int-6 resulted in spliced RNA containing 
mainly exons 5 + 6 + 8 + 9. We also determined the 
effects of deleting sequences between some of the clus- 
tered point mutations. Thus, three mutant plasmids 
were constructed, designated int3-5, int2-5, and intl-6, 
which contain deletions between the corresponding 
clustered point mutations hown in Figure 1. These con- 
structs were tested in vivo by cloning the corresponding 
deletions into plasmid pSV40-2 (Helfman et al. 1988, 
1990). HeLa cells were transfected with the wild-type 
and three deletion mutants, and 48 hr later the cytoplas- 
mic RNA was isolated and analyzed by RNA protection 
(Fig. 2B). Transient expression of the wild-type plasmid 
pSV40-2 in HeLa cells resulted in spliced RNA that con- 
tains exons 5 + 6 + 8 + 9. There was no skeletal mus- 
cle-type splice with the wild-type construct, that is, ex- 
ons 5 + 7 + 8 + 9. In contrast, transient expression of 
the minigenes containing the three mutations resulted 
predominately in spliced RNA containing exons 
5 + 7 + 8 + 9 (skeletal muscle-type splice) (Fig. 2B). 
These results indicate hat specific sequences in the 3' 
end of intron 6 are involved in blocking the use of exon 
7 in HeLa cells. 
Nucleotide substitutions within the skeletal 
muscle-specific exon 7 also result in the use 
of exon 7 in nonmuscle cells 
To analyze the role of sequences contained within exon 
7 we introduced a series of clustered point mutations 
into four separate regions of the skeletal muscle exon. 
The sequence of exon 7 and the position of the exon 
substitutions are indicated in Figure 1. The substitutions 
were introduced into plasmid pSV40-2 for in vivo anal- 
yses (Fig. 3). HeLa cells were transfected with the wild- 
type and four mutant plasmids (Ex-1 through Ex-4) and 
analyzed as described above. Because the clustered point 
mutations introduce regions of noncomplementarity to 
the wild-type cDNA probe encoding the skeletal muscle 
RNA, the protected fragments are digested at an internal 
position. The positions of the two protection fragments 
resulting from splicing of exons 5 + 7 + 8 + 9 are indi- 
cated in Figure 3. The Ex-1 mutation, which alters 5 
nucleotides near the 5' end of exon 7, was the strongest 
activating exon mutation, resulting in spliced RNA con- 
taining the skeletal muscle-type splice and no detectable 
levels of spliced RNA containing exon 6 (Fig. 3). The 
other mutations within exon 7 resulted in different lev- 
els of activation of the skeletal muscle-type splice. These 
results indicate that cis-acting elements necessary for 
tissue-specific splicing are also contained within exon 7. 
Sequences downstream of exon 7 do not affect 
alternative splice-site selection in nonmuscle cells 
We and others have suggested previously that sequences 
contained within exon 7, as well as upstream and down- 
stream intron sequences, might form an RNA secondary 
structure that prevents the use of this exon in nonmus- 
cle cells (Helfman et al. 1988, 1990; Libri et al. 1989, 
1990). To determine whether specific sequences within 
intron 7 are required for regulating the use of exon 7 in 
nonmuscle cells we introduced a series of deletions in 
this intron (Fig. 1). The deletions were introduced into 
plasmid pSV40-2 for in vivo analyses (Fig. 4). Transient 
expression of the wild-type and six mutant  plasmids in 
HeLa cells resulted in spliced RNA that contains exons 
5 + 6 + 8 + 9 and almost undetectable levels of the 
skeletal muscle-type spliced RNA (Fig. 4). In no case did 
we observe activation of the skeletal muscle exon with 
any of the deletions tested. These results demonstrate 
that intron sequences downstream of exon 7 do not play 
a role in the regulation of alternative splice-site selection 
of this exon in nonmuscle cells. 
Inactivation of exon 6 does not result in increased 
use of the skeletal muscle-specific exon 7 
in nonmuscle cells 
We then determined whether alternative splicing is due 
to a simple cis-acting competition for splice sites. For 
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Figure 2. (A) Nucleotide substitutions within intron 6 result in the use of the skeletal muscle-specific exon (exon 7) in nonmuscle 
cells. Clustered point mutations where introduced into six regions of intron 6 (indicated int-1 through int-6; see also Fig. 1). (Top) 
Schematic diagram of the tropomyosin minigene used in the HeLa cell transfection. (Middle) Autoradiographs of RNA protection 
analyses with eDNA probes derived from eDNA clones encoding rat fibroblast TM-1 {left) and skeletal muscle B-TM (right). The band 
corresponding to the reference ~-globin RNAs is labeled. The identity of the band just below the a-globin protection products likely 
represents he protection of sequences containing exons 8 + 9. (Bottom) Schematic diagram of the structure of the RNA probe and 
protected fragments ( plice products). It is worth noting that because both exon 6 and exon 7 each contain 76 nucleotides, the splice 
products resulting from the use of each exon are the same number size. {B). Deletions in intron 6 result in the use of exon 7 in 
nonmuscle cells. Mutations were constructed in the 3' end of intron 6 by deleting the sequences between the given clustered point 
mutations hown in Fig. 1. Schematic diagram of the tropomyosin minigenes used and autoradiographs of RNA protection analyses are 
as described in A. 
example, if exon 6 splice junctions are intrinsically more 
efficient than those of exon 7 in nonmuscle cells, then 
inactivating the competing splice sites should result in 
increased use of the skeletal splice in HeLa cells. To test 
this hypothesis, a series of deletions and point mutations 
were introduced into the 5'- and 3'-splice sites of exon 6 
(Fig. 5). The 5'-splice site of exon 6 was either deleted by 
removing the NcoI/StuI fragment containing the 3' end 
of exon 6 and 17 nucleotides of downstream intron, or 
inactivated by two point mutations that changed the 
conserved GT dinucleotide to GA or AT. Similarly, the 
3'-splice site of exon 6 was either deleted by removing 
the MstII/NcoI fragment containing 100 nucleotides of 
upstream intron and the 5' end of exon 6, or inactivated 
by a point mutation that changed the conserved AG di- 
nucleotide to CG. The substitutions were introduced 
into plasmid pSV40-2 for in vivo analyses (Fig. 5). As 
expected, transient expression of the wild-type plasmid 
pSV40-2 in HeLa cells resulted in spliced RNA that con- 
tains exons 5 + 6 + 8 + 9. Transient expression of the 
minigenes containing mutations in the 5'- and 3'-splice 
sites of exon 6 resulted in virtually undetectable vels of 
spliced RNA containing this exon. However, in no case 
did we observe increased use of the skeletal muscle exon 
with any of the mutant constructs. These results dem- 
onstrate that the lack of use of skeletal muscle exon is 
not due to a simple cis-acting competition mechanism 
but, rather, to a mechanism that blocks the use of the 
skeletal muscle exon (exon 7) in nonmuscle cells. 
Two different mechanisms could explain why exon 7 
is excluded in nonmuscle cells. The first might involve 
muscle-specific factors that activate the splicing of exon 
7. For example, we and others have speculated that exon 
7 is sequestered in a secondary structure, which is dis- 
rupted by muscle-specific factors to permit the use of 
this exon (Goux-Pelletan et al. 1990; Helfman et al. 
1990; D'Orval et al. 1991). The second mechanism ight 
involve specific cellular factors that block the use of the 
skeletal muscle-type splice. We reasoned that if a cellu- 
lar factor repressed the use of the skeletal muscle exon 
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thus allows amplification of the tropomyosin plasmid. 
As indicated in Figure 6, coexpression of T antigen re- 
sulted in spliced RNA containing either exon 6 or exon 
7. These results provide evidence to suggest hat HeLa 
cells contain limited amounts of factors that block the 
use of the skeletal muscle splice. 
A HeLa nuclear protein binds to the intron element 
that inhibits the use of the skeletal muscle-specific 
exon in nonmuscle cells 
Having localized the sequences in the pre-mRNA that 
play an important role in regulated altemative splice site 
selection to the 3' end of intron 6 and exon 7, we then 
examined the ability of RNA containing these sequences 
to interact with factors present in nuclear extracts. We 
used an RNA mobility-shift assay on nondenaturing 
polyacrylamide gels to detect the interaction of cellular 
factors with the 3~p-labeled RNA. When a wild-type 
RNA probe, termed Ex-7, which contains 90 nucleotides 
of intron sequences upstream of exon 7, exon 7, and 25 
nucleotides of intron sequences downstream of exon 7 
(see diagram in Fig. 7J, was incubated with unfraction- 
ated HeLa cell nuclear extracts, bands with retarded mo- 
bility were detected. It is important o note that the con- 
Figure 3. Sequences in exon 7 play a role in alternative splice- 
site selection. Clustered point mutations where introduced into 
four regions of exon 7 {indicated Ex-1 through Ex-4; see also Fig. 
1). Schematic diagram of the tropomyosin minigenes used and 
autoradiographs of RNA protection analyses are as described in 
Fig. 2A. Because the clustered point mutations introduce re- 
gions of noncomplementarity to the wild-type cDNA probe en- 
coding the skeletal muscle RNA, the protected fragments are 
digested at an internal position and their position of two result- 
ing fragments are indicated at right (arrows). 
by binding to the pre-mRNA, it might be possible to 
overcome this inhibition by introducing large quantities 
of pre-mRNA into a cell and thereby titrate the inhibi- 
tory factor. Accordingly, we transfected increasing 
amounts of the wild-type plasmid in HeLa cells and de- 
termined the patterns of altematively spliced RNAs (Fig. 
6). In transfections with 1.0-5.0 ~g of plasmid, only fully 
spliced RNA containing exons 5 + 6 + 8 + 9 was de- 
tected. In contrast, transfection of 10-20 ~.g of plasmid 
resulted in use of the skeletal muscle-type splice in HeLa 
cells. In addition, because our tropomyosin minigene 
plasmid contains an origin of replication for T antigen, 
we cotransfected 2 ~g of the wild-type tropomyosin 
minigene with a plasmid that expresses T antigen and 
Figure 4. Deletion of sequences downstream of exon 7 does 
not affect alternative splice-site selection in nonmuscle cells. 
The positions of the deletions are shown in Fig. 1. Schematic 
diagram of the tropomyosin minigenes used and autoradio- 
graphs of RNA protection analyses are as described in Fig. 2A. 
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tains a protein component because addition of either 
SDS or proteinase K completely eliminated complex for- 
mation (data not shown). In addition, the complex was 
sequence-specific because 32p-labeled RNAs containing 
regions in and around exon 6 (Ex-6 RNA) and exon 8 
(Ex-8 RNA) did not form a complex (Fig. 8A). We also 
tested the ability of RNAs that contained deletions in 
the 3' end of intron 6 to form a complex. Accordingly, 
three mutants, designated int3-5, int2-5, and intl-6 con- 
tain deletions between the corresponding clustered mu- 
tations shown in Figure 1. These mutations were chosen 
because they result in almost complete use of the skel- 
etal muscle exon in vivo (Fig. 2B). As indicated in Figure 
8A, all three mutations completely disrupt complex for- 
mation, indicating that these intron sequences are criti- 
Figure 5. Inactivation of exon 6 does not lead to the use of the 
skeletal muscle exon in nonmuscle cells. Schematic diagram of 
the tropomyosin minigenes used and autoradiographs of RNA 
protection analyses are as described in Fig. 2A. 
centration of the nuclear extract used in the gel-shift 
assay was a critical parameter. When the wild-type con- 
struct (Ex-7) was incubated with increasing amounts of 
nuclear extract, a band of slower mobility than free RNA 
was observed (Fig. 7). This complex reflects the binding 
of a cellular factor to the RNA. In addition, the complex 
was sequence specific because 32p-labeled RNAs con- 
taining a deletion at the 3' end of intron 6 (int3-5) did 
not form a complex (Fig. 7). However, at the highest con- 
centrations of nuclear extract (lane 6) it was difficult to 
show specificity for wild-type versus mutant  constructs 
because both species of RNA molecules exhibited a gel 
shift (Fig. 7). These results demonstrated that HeLa cell 
nuclear extracts contain a factor that binds to sequences 
at the 3' end of intron 6. 
We then fractionated HeLa cell nuclear extracts with 
phosphocellulose and S-Sepharose column chromatogra- 
phy, using the gel mobility-shift assay to follow the bind- 
ing activity in each fraction with the wild-type construct 
and the deletion mutant  shown in Figure 7 (see also Ma- 
terials and methods). Fractions from the S-Sepharose col- 
umn were used for all subsequent characterization f the 
RNA-binding activity. When the wild-type construct 
(Ex-7) was incubated with the partially purified fractions 
from the S-Sepharose column, a band of slower mobility 
than free RNA was observed {Fig. 8A). The complex con- 
Figure 6. Transfection of increasing amounts of the wild-type 
tropomyosin minigene plasmid into HeLa cells results in acti- 
vation of the skeletal muscle-type s lice in nonmuscle cells. 
HeLa ceils were transfected with the wild-type tropomyosin 
minigene pSV40-2 at the concentrations indicated (0, 0.1, 1.0, 
2.5, 5.0, 10, and 20 g~g), or 2 ~g of the wild-type minigene was 
cotransfected with a plasmid that expresses T antigen and cy- 
toplasmic RNA harvested 48 hr later. To control for the amount 
of DNA in each transfection, carrier DNA was adjusted to main- 
tain a total DNA concentration of 20 ixg per transfection. The 
schematic diagram of the tropomyosin minigene used and au- 
toradiograph of RNA protection analyses are as described in Fig. 
2A. The identity of the band that increases in intensity with 
increasing amounts of transfected plasmid located just below 
the c~-globin protection products likely represents the protec- 
tion of sequences containing exons 8 + 9. The identity of the 
band detected with the skeletal muscle probe at high concen- 
trations of DNA and in the presence of T antigen is unknown. 
(Bottom) Schematic diagram of the structure of the RNA probe 
and protected fragments ( plice products). 
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Figure 7. HeLa cell nuclear extracts contain factors that inter- 
act with the 3' end of intron 6. 32p-Labeled RNAs were incu- 
bated with unfractionated HeLa cell nuclear extracts {lanes 1-6) 
and fractions from the S-Sepharose column (see Materials and 
methods), and separated on a denaturing 4% polyacrylamide 
gels. Lanes 1-6 contained 0.4, 1.0, 2, 4, 8, and 20 ttg of protein, 
respectively. Each concentration of extract was assayed with 
the wild-type {left) and mutant (right)a2P-labeled RNA. The po- 
sition of the free RNA and complex are indicated at left. A 
schematic diagram of the structures of the RNA used in the gel 
mobility-shift assay is shown at right. 
cal for the interaction of the RNA with the binding pro- 
teins. These results correlate with the in vivo results and 
suggest that the mutations function in vivo as a result of 
the inabil ity of the RNA to form a complex with these 
cellular factors. 
To determine the specificity of the interaction of the 
wild-type Ex-7 RNA with cellular factors we carried out 
a series of competition experiments using wild-type, mu- 
tant, and nonspecific ompetitors. Wild-type Ex-7 RNA 
labeled with 32p was assayed in the presence of different 
competitors, as indicated in Figure 8B. Addition of unla- 
beled wild-type RNA resulted in a dose-dependent reduc- 
tion in the formation of the complex (Fig. 8B). In con- 
trast, addition of the other three unlabeled RNAs con- 
taining a mutation in the 3' end of intron 6 {int-3), 
sequences around exon 6 (Ex-6) and exon 8 (Ex-8) had no 
effect on complex formation (Fig. 8B). To study further 
the region involved in complex formation unlabeled 
RNAs representing different regions of the wild-type 
Ex-7 RNA were used as competitors (Fig. 8C). Only the 
wild-type RNA and RNA-containing sequence in the 3' 
end of intron 6 (WT-3') were able to compete with 32p_ 
labeled wild-type probe for complex formation. It is 
worth noting that the uppermost shift observed with the 
Ex7-5' competitor at 1000 ng is a result of the formation 
of an intermolecular hybrid molecule formed between 
the 32 P-labeled RNA and the competitor. These results 
indicate that the intron sequences upstream of the 3'- 
splice site of exon 7 are critical for complex formation. 
Discuss ion  
The role of RNA secondary structure in alternative 
splicing of f3-TM pre-RNA 
Previous studies of alternative splicing of the rat and 
chicken [3-TM genes have suggested that one possible 
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mechanism by which the use of exon 7 is regulated in 
nonmuscle and skeletal muscle cells is by regulation of 
RNA secondary structure (Helfman et al. 1988, 1990; 
Libri et al. 1989, 1990, 1991; D'Orval et al. 1991; see also 
Fig. 9). Computer analysis of intron sequences upstream 
and downstream of exon 7 in the rat and chicken genes 
predicts that these RNA sequences can theoretically 
form a stable secondary structure that would sequester 
the 5'- and 3'- splice sites of this exon from the splicing 
machinery and thereby prevents its use in nonmuscle 
cells. This phylogenetically conserved, putative second- 
ary structure could then be subject o regulation via cel- 
lular factors that would either stabilize or destabilize the 
structure in nonmuscle and skeletal muscle cells, re- 
spectively, and thereby lead to the use of this exon in a 
tissue-specific manner. This model would predict that 
intron sequences upstream as well as downstream of 
exon 7 would contain cis-acting elements necessary for 
regulating the use of exon 7 in nonmuscle cells. How- 
ever, three sets of experiments presented in this study 
provide strong evidence against a mechanism based 
solely on RNA secondary structure. First, the removal of 
intron sequences downstream of exon 7 did not result in 
activation of the skeletal muscle exon in nonmuscle 
cells (Fig. 4). Second, the activation of the skeletal mus- 
cle splice observed following the introduction of clus- 
tered point mutations in intron 6 and exon 7, which 
changed as few as three nucleotides in the pre-mRNA, 
would not be expected to disrupt the extensive second- 
ary structure needed to sequester exon 7 (Figs. 2A and 3). 
Third, overexpression f the pre-mRNA resulted in acti- 
vation of the skeletal muscle exon, presumably the re- 
sult of titration of some inhibitory activity (blocking fac- 
tors) in nonmuscle cells (Fig. 6). Therefore, on the basis 
of the considerations given above, it is unl ikely that al- 
ternative splicing of the rat B-TM gene will involve the 
kind of secondary structure proposed for the chicken 
[3-TM gene (Libri et al. 1990; D'Orval et al. 1991). 
Although alternative splicing of the rat B-TM gene 
does not appear to require a secondary structure involv- 
ing intron sequences downstream of exon 7, a more lim- 
ited structure localized to sequences within exon 7 could 
be involved in tissue-specific splicing. Both rat and 
chicken [3-TM genes contain a phylogenetically con- 
served secondary structure within the skeletal muscle 
exon (Helfman et al. 1990; Libri et al. 1990, 1991). The 
sequences contained in exon 7 are able to form a second- 
ary structure, comprised of a stem-loop (Helfman et al. 
1990; Libri et al. 1990). Strong evidence that such a 
structure does exist comes from recent studies of the 
chicken [3-TM gene (Libri et al. 1991). Using compensa- 
tory base substitutions these studies revealed that se- 
quences confined to the skeletal muscle exon were re- 
quired for regulated alternative splicing and that these 
sequences function, i  part, by a secondary structure 
(Libri et al. 1991). The results presented in this paper also 
demonstrate that similar sequences contained within 
exon 7 of the rat [3-TM gene function in splice-site se- 
lection (Fig. 3). In addition, the mutations that showed 
the strongest activation of the skeletal muscle exon, that 
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Figure 8. Cellular factors interacting with [~-TM RNA. (A) Identification 
of proteins that bind to tropomyosin RNA by a gel mobility-shift assay. 
gaP-Labeled RNAs were incubated with fractions from the S-Sepharose 
column (see Materials and methods) and separated on a denaturing 4% 
polyacrylamide g ls. The positions of the free RNA and complex are indi- 
cated at left. A schematic diagram of the structures of the RNA used in the 
gel mobility-shift assay is shown at right. (B) Competition experiments 
showing that the complex is sequence specific. Binding reactions were 
carried out using gaP-labeled Ex-7 RNA (see A). The gaP-labeled RNA was 
incubated with fractions from the S-Sepharose column (see Materials and 
methods) in the presence of wild-type, int-3, Ex-6, and Ex-8 unlabeled 
competitor RNAs at the concentrations indicated and separated on a de- 
naturing 4% polyacrylamide g l. The position of the free RNA and com- 
plex are indicated at left; a schematic diagram of the structures of the competitor RNAs used in the gel mobility-shift assay is shown 
at right. (C) Competition experiments showing that the 3' end of intron 6 contains equences important for binding. Binding reactions 
were carried out by using gaP-labeled Ex-7 RNA (see A). The 3~p-labeled RNAs were incubated with fractions from the S-Sepharose 
column (see Materials and methods) in the presence of wild-type, int-3, WT-3', and Ex7-5', unlabeled competitor RNAs at the 
concentrations indicated and separated on a denaturing 4% polyacrylamide gel. The positions of the free RNA and complex are 
indicated at left; a schematic diagram of the structures of the competitor RNAs used in the gel mobility-shift assay is shown at right. 
is, Ex-1 (Fig. 3), would disrupt the stem of the predicted 
RNA structure. Thus, a secondary structure localized to 
those sequences within the skeletal muscle exon likely 
plays a role in regulated alternative splice-site selection. 
The role of distant branch sites in alternative 
splice-site selection 
Branch sites located an unusually long distance from a 
3'-splice site (i.e., >40 nucleotides) are a general feature 
of some alternatively excised introns and function in at 
least two ways in alternative splice-site selection. The 
best-studied examples involve the rat oL-TM gene and the 
rat and the chicken f~-TM genes (Helfman et al. 1989, 
1990; Smith and Nadal-Ginard 1989; Goux-Pelletan 
1990; Libri et al. 1990; Mullen et al. 1991; this study). In 
the case of the rat a-TM gene, the use of a distant branch 
site plays a direct role in preventing the splicing together 
of the two mutual ly exclusive exons 2 and 3 (Smith and 
Nadal-Ginard 1989). These two exons are never spliced 
together in any cell type. The molecular basis for this is 
the proximity of the 5'-splice site of exon 2 relative to 
the branchpoint used for exon 3, which is only 42 nucle- 
otides apart. In contrast, this mechanism cannot explain 
the mutual ly exclusive use of exons 6 and 7 in the rat 
and chicken B-TM genes, because the 5'-splice site of 
exon 6 in these genes is located at least 136 nucleotides 
upstream of the branchpoints used for the skeletal mus- 
cle exon (Helfman et al. 1989, 1990; Goux-Pelletan et al. 
1990). Thus, the distant branchpoints of the [3-TM genes 
in rat and chicken play a different role in alternative 
splicing. It is clear from this and previous studies that 
intron sequences located between the branchpoint and 
downstream 3'-splice site contain important informa- 
tion for splice-site selection because deletion or muta- 
tion of these sequences results in the use of the skeletal 
muscle exon in nonmuscle cells (Helfman et al. 1990; 
Libri et al. 1990; this study}. These sequences appear to 
function by providing a binding site for cellular factors 
that regulate tissue-specific splicing (see below). 
Cellular factors involved in alternative splice-site 
selection 
The in vitro binding studies show that intron sequences 
upstream of exon 7 bind specifically to cellular factors 
(Figs. 7 and 8). Although the nature of these factors, the 
mechanism of their action, and a precise definition of the 
sequences in the pre-mRNA that they bind to remains to 
be determined, it is clear from our studies that the bind- 
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It remains to be determined whether the cellular fac- 
tors identified in this study bind to a linear RNA mole- 
cule or whether they recognize RNA secondary structure 
(Fig. 9). As discussed above, although it is unl ikely that 
an extensive secondary structure prevents the use of 
exon 7 in nonmuscle cells, a local secondary structure 
within exon 7 could provide a binding site for factors 
(Fig. 9). For example, the binding of the HIV rev protein 
to the rev-response elements requires a secondary struc- 
ture (Olsen et al. 1990). It is worth noting that none of 
the clustered point mutations in exon 7 affected the 
binding of the RNA to the factors identified in the 
present studies (data not shown). These results suggest 
that a factor bound to the intron might also bind to the 
exon or that a different factor might interact with the 
exon sequences. Thus, it remains to be determined 
whether the intron and exon mutations act via the same 
mechanism and cellular factors. 
Figure 9. Possible mechanisms bywhich exon 7 is excluded in 
nonmuscle cells (for explanation see, Discussion). 
ing sites of these factors correlate with sequences re- 
quired to prevent the use of the skeletal muscle splice in 
nonmuscle cells. Although we found that clustered point 
mutations in the 3' end of intron 6 resulted in use of the 
skeletal muscle-type splice n nonmuscle cells, no single 
mutation of this type was able to completely activate the 
use of exon 7, that is, there was still use of exon 6 (Fig. 
2A). This is in contrast o the deletions that lead to com- 
plete use of exon 7 (Fig. 213; Helfman et al. 1990). In 
addition, these mutations in the 3' end of intron 6 are 
located over a stretch of at least 40 nucleotides. These 
results would suggest hat either a single factor binds to 
multiple sites on the pre-mRNA or multiple factors bind 
to mult iple sites on the pre-mRNA. We have observed 
that the 3' end of intron 6 in the rat B-TM gene contains 
seven overlapping copies of an 11-nucleotide imperfect 
repeat, with the sequence YR(Y)4R(Y)2RY [(Y), pyrimi- 
dine; (R) purine] (Fig. 1). Interestingly, the locations of 
the four repeats correspond to the position of the four 
clustered point mutations (int-2, int-3, int-4, and int-5) 
that resulted in the use of exon 7 in nonmuscle cells (Fig. 
2B). Whether or not the repeats in the tropomyosin gene 
represent rue binding sites for cellular factors is cur- 
rently being studied. Recently, six copies of a 13-nucle- 
otide imperfect repeat was identified in the pre-mRNA 
of the dsx gene of Drosophila melanogaster and is re- 
quired for binding specifically to the tra-2 protein (Hed- 
ley and Maniatis 1991). 
Mechanisms of alternative splice-site selection 
The mechanism by which factors binding to the pre- 
mRNA block the use of exon 7 in nonmuscle cells re- 
mains to be elucidated. One possibility is that the bind- 
ing of factors to the RNA results in the formation of a 
ribonucleoprotein (RNP) structure, which prevents the 
interaction of splicing factors with the 5'- and 3'-splice 
sites of exon 7. Alternatively, individual general splicing 
factors such as U1 small nuclear RNP (snRNP), U2 sn- 
RNP, U2AF (Zamore and Green 1989), and ASF/SF2 
could be targets for the actions of a blocking factor. 
Thus, a blocking factor bound to the RNA might prevent 
the interaction of general splicing factors with the pre- 
mRNA and thereby inhibit the use of a particular splice 
site. Because ASF/SF2 affects the use of 5'-splice sites 
(Ge and Manley 1990; Krainer et al. 1990a), it is possible 
that the action of this splicing factor might also be sub- 
ject to regulation by factors that antagonize its func- 
tions. A major determinant in splice-site strength is the 
pyrimidine content adjacent to the branchpoint se- 
quences; the longer the pyrimidine tract, the more favor- 
able the splice is (Mullen et al. 1991). Although exon 7 
contains a lengthy polypyrimidine tract associated with 
the use of its 3'-splice site, it is normally not used in 
nonmuscle cells. A polypyrimidine tract-binding protein 
has been identified, whose binding correlates with the 
relative use of a 3'-splice site (Garcia-Blanco et al. 1989; 
Mullen et al. 1991). The interaction of this polypyrimi- 
dine tract-binding protein could also be involved in reg- 
ulated alternative splice-site selection. 
Whether or not the factors identified in this study are 
expressed in a tissue-specific manner emains to be de- 
termined. For example, one prediction from this study 
would be that in skeletal muscle these blocking factors 
are no longer expressed or become inactivated. In the 
absence of functional blocking factors the skeletal mus- 
cle exon would become the default splice choice. The 
long polypyrimidine tract associated with the 3'-splice 
site of exon 7 may be sufficient, in the absence of block- 
ing factors, to allow exon 7 to become the "default" 
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splice choice, simply the result of the more competitive 
nature of the adjacent 3'-splice site relative to exon 6. 
Support for this model comes from experiments showing 
that mutations in the 3' end of intron 6 can lead to ex- 
clusive use of the skeletal muscle splice in nonmuscle 
cells (Helfman et al. 1990; this study). On the other 
hand, recent work on ASF/SF2, showing that concentra- 
tions of a single factor can effect the use of alternative 
splice sites, raises the possibi l i ty that alternative splic- 
ing could, in principle, arise by changes in the relative 
concentrat ions of various factors (Ge and Manley 1990; 
Krainer et al. 1990a). Thus, differences in the relative 
concentrat ions of the factors identif ied in this study 
could be responsible for regulated alternative splicing. 
Finally, addit ional factors might  be required for regula- 
tion. For example, the factors identif ied in the present 
studies once bound to the pre-mRNA might  then bind to 
other cellular factors that modulate the use of exon 7 in 
a tissue-specific manner.  
In summary,  having identif ied cellular factors that in- 
teract wi th  specific sequences in the pre-mRNA we can 
now direct our efforts to a greater understanding of how 
these factors act to regulate alternative splicing. Work is 
in progress to purify the factor(s) that interact wi th  the 
RNA, to precisely identi fy the sequences to which they 
bind, and to develop in vitro assays to identify their func- 
tion. 
Materials and methods 
Plasmid constructions 
For studies designed to analyze the internal alternatively 
spliced region of the rat [3-TM gene in vivo plasmids pSV40-p2 
were used (Helfman et al. 1988). The indicated mutations were 
subcloned into plasmid pSV40-p2. In all transfection studies 
HeLa cells were cotransfected with an a-globin test gene (Tre- 
isman et al. 1983; Herr and Clarke 1986). 
The DNA templates for use in in vitro transcription are de- 
rived from the rat B-TM gene (Helfman et al. 1986). The se- 
quences of all mutations were determined by DNA sequence 
analysis (Sanger et al. 1977) and are shown in Figure 1. 
Oligonucleotide site-directed mutagenesis 
Clustered point mutations, which introduced a BamHI site in 
the DNA, were introduced into intron 6 and exon 7 by oligo- 
nucleotide mutagenesis (Kunkel 1985). Mutations in the 5' GU 
dinucleotide and 3'-splice site AG dinucleotide of exon 6 were 
also introduced by the method of Kunkel (1985). The mutations 
were confirmed by sequencing the DNA (Sanger et al. 1977). 
Nuclear extract and fractionation 
Sonicated and double-extracted nuclear extracts were prepared 
as described previously starting with 8 liters of HeLa cells that 
were grown to a density of 1 x 106/liter (Krainer et al. 1990b). 
All steps were carried out at 4~ The nuclear extract material 
was dialyzed against buffer D ([20 mm HEPES (pH 8.0}, 100 mM 
KCI, 0.2 mM EDTA, 0.5 mM DTT, 5% glycerol]). The nuclear 
extract was brought o 20% ammonium sulfate by the addition 
of solid ammonium sulfate (10.6 g/100 ml). The solution was 
stirred gently for 30 min and centrifuged for 30 min at 2300g to 
remove the precipitated was proteins. The supernatant was 
brought to 50% ammonium sulfate by the addition of solid 
ammonium sulfate (17.5 g/100 ml). The solution was stirred 
gently for 30 min and the precipitate was recovered by centrif- 
ugation for 30 min at 2300g. This 20-50% ammonium sulfate 
pellet was resuspended in buffer containing 20 mM HEPES (pH 
8.0), 100 mM KC1, 2 mM EDTA, 5% glycerol, 0.02% NP-40, 0.5 
mM DTT, and 0.5 mM PMSF. The protein concentration was 
adjusted in the same buffer to 4 mg/ml and loaded on a What- 
man Pl l  phosphocellulose column (15 x 1.5 cm). The column 
was washed with 30 ml of buffer D and then eluted stepwise in 
buffer D containing 150 mM, 350 mM, and 1000 mM KC1. Each 
step was collected in 6 x 5-ml fractions. Each fraction from the 
wash, 150 mM, 350 mM, and 1000 mM KC1 elutions, was col- 
lected and assayed for RNA-binding proteins. Most of the bind- 
ing activity was found in the 350 mM KC1 fraction. The material 
from this fraction was adjusted to 100 mM KC1 and loaded onto 
a 10-ml Pharmacia S-Sepharose column. The column was 
washed with 30 ml of buffer D and eluted stepwise in buffer D 
containing 150 mM, 300 mM, and 500 mM KC1. Each step was 
collected in 4 x 5-ml fractions. Each fraction from the wash, 
150 mM, 300mM, and 500 mM KC1 elutions, was collected and 
assayed for RNA-binding proteins. The majority of the RNA- 
binding activity was found in the 150 mM elution and was used 
for further characterization. 
RNA mobility-shift assay 
The RNA mobility-shift assays were performed ssentially ac- 
cording to Konarska and Sharp (1986). The 3~p-labeled SP6/ 
tropomyosin transcripts were synthesized in vitro primed with 
CAP analog as described (Konarska et al. 1984). The 32p-labeled 
pre-mRNAs were further purified on acrylamide/urea gels. The 
protein-RNA complexes were s parated by native gel electro- 
phoresis using 4% acrylamide gels (acrylamide/bis, 29 : 1) by 
using TBE (89 mM Tris base, 89 mM boric acid, 2 m~4 EDTA) as 
a running buffer. The gels (25 x 0.15 cm) were pre-electropho- 
resed at 10 V/cm for 1 hr prior to loading samples. Binding 
reactions were performed in a 25-~1 reaction containing, 20 mM 
HEPES (pH 8.0), 5% glycerol, 70 mM KC1, 3 mM MgC12, 3 units 
of RNasin, 1 ~g of tRNA, 0.5 mM ATP, 20 mM creatine phos- 
phate, 5-20 ~g of protein, and uniformly 32p-labeled RNA 
probe. After 30 min of incubation at 30~ the sample was ad- 
justed to 5 mg/ml with heparin and incubated at 30~ for 10 
rain. One microliter of loading buffer containing 97% glycerol 
and 0.01% bromphenol blue plus 0.01% xylene cyanol was 
added just before loading the sample on the gel. The gel was 
electrophoresed at room temperature at 10 V/cm until the xy- 
lene cyanol had migrated 12-13 cm. The gels were dried and 
visualized by autoradiography. 
Transfections and RNA analysis 
HeLa cells were grown in Dulbecco's modified Eagle medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS). Un- 
less otherwise indicated, HeLa cells were transfected with 5 ~g 
of tropomyosin plasmid DNA and 1 ~g of ~-globin test plasmid 
(Treisman et al. 1983) per 100- mm plate by using a calcium 
phosphate coprecipitation procedure; cells were harvested 48 hr 
later, and the cytoplasmic RNA was isolated as described pre- 
viously (Helfman et al. 1988, 1990). The a-globin plasmid served 
as an internal control for transformation efficiency. RNase pro- 
tection assays were carried out as described (Zinn et al. 1983). 
The plasmids used for synthesis of 82p-labeled antisense RNA 
were derived from eDNA clones encoding rat fibroblast TM-1 
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and skeletal muscle ~3-TM and have been described elsewhere 
(Helfman et al. 1988, 1990). 
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